This ACTU site plans to continue to be an active participant in HIV clinical trials. One hundred patients per year emphasizing earlier phase trials will be enrolled. It is proposed that this site will enroll 15 patients per year into phase I studies, 20 patients per year into phase I/II studies, 25 patients per year in phase II studies, and 40 patients per year into phase III clinical trials. The focus of the investigations will be influenced by the nature of the patients seen at the institution and available for ACTG supported studies. This patient population is ideal for the study of primary antiretroviral therapy in patients with advanced disease or for studies of newer agents for opportunistic infections. The number of patients is anticipated to continue to grow, making this institution capable of enrolling patients in multiple clinical trials. The principal focus of primary infection studies will be on newer therapies, particularly in advanced disease. Phase I and/or phase I/II studies in such patients are planned followed by combination therapies. Combining immunomodulators with primary antiretroviral studies is proposed. Studies in opportunistic infections will concentrate on the development of new agents for acute infections. The Gastroenterology and Pulmonary collaborators will facilitate studies of new therapies involving those organ systems. The Oncology co-investigator will facilitate studies of the therapy for HIV-associated malignancies. The Neurology collaborator will guide participation in studies of therapies aimed at neurologic complications of HIV infection or opportunistic infections involving the nervous system. Development of a collaborative group from multiple disciplines which will focus on development of new therapies for HIV infection and opportunistic infection will provide a broad range of expertise. Innovative protocol development will be a priority of this study group whose goal is to improve therapeutic options available to patients as quickly as possible.

Project Start
Project End
Budget Start
Budget End
Support Year
4
Fiscal Year
1995
Total Cost
Indirect Cost
Name
University of Texas Medical Br Galveston
Department
Type
DUNS #
041367053
City
Galveston
State
TX
Country
United States
Zip Code
77555
Martin, Maureen P; Naranbhai, Vivek; Shea, Patrick R et al. (2018) Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. J Clin Invest 128:1903-1912
Haas, David W; Bradford, Yuki; Verma, Anurag et al. (2018) Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. Pharmacogenet Genomics 28:179-187
Venuto, Charles S; Lim, Jihoon; Messing, Susan et al. (2018) Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s. Antivir Ther 23:345-351
Li, Binglan; Verma, Shefali S; Veturi, Yogasudha C et al. (2018) Evaluation of PrediXcan for prioritizing GWAS associations and predicting gene expression. Pac Symp Biocomput 23:448-459
Gupta, Samir K; Yeh, Eunice; Kitch, Douglas W et al. (2017) Bone mineral density reductions after tenofovir disoproxil fumarate initiation and changes in phosphaturia: a secondary analysis of ACTG A5224s. J Antimicrob Chemother 72:2042-2048
Verma, Anurag; Bradford, Yuki; Verma, Shefali S et al. (2017) Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202. Pharmacogenet Genomics 27:101-111
Bednasz, Cindy J; Venuto, Charles S; Ma, Qing et al. (2017) Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants. Ther Drug Monit 39:596-603
Verma, Shefali S; Frase, Alex T; Verma, Anurag et al. (2016) PHENOME-WIDE INTERACTION STUDY (PheWIS) IN AIDS CLINICAL TRIALS GROUP DATA (ACTG). Pac Symp Biocomput 21:57-68
Moore, Carrie B; Verma, Anurag; Pendergrass, Sarah et al. (2015) Phenome-wide Association Study Relating Pretreatment Laboratory Parameters With Human Genetic Variants in AIDS Clinical Trials Group Protocols. Open Forum Infect Dis 2:ofu113
Lehmann, David S; Ribaudo, Heather J; Daar, Eric S et al. (2015) Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols. Pharmacogenet Genomics 25:51-9

Showing the most recent 10 out of 102 publications